AIMS Cancer Outcomes Study

Part of paid clinical trials in Seattle, Washington.

Sponsor
Advanced Integrative Medical Science Institute
Study ID
NCT04495790
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Cancer
  • Advanced Solid Tumor
  • Neoplasm Malignant
  • Neoplasms
  • Oncology

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.

Key Dates

Start date
May 18, 2020
Status verified
Jan 2023
Primary completion
May 18, 2025
Completion
Dec 31, 2030

Study Design

Enrollment
500 participants (estimated)

Primary Outcome Measure

AIM 1 (survival) [ Time Frame: 5 Years ]

Locations (1)

FacilityCityStateZIPSite coordinators
AIMS InstituteSeattleWashington98102
Michelle Speaks, MBA
[email protected]
2064201321
Sunil K Aggarwal, MD, PhD, FAAPMR
[email protected]
2064201321
Therry Eparwa, DNP, ARNP, FNP-BC (PRINCIPAL_INVESTIGATOR)
Leanna J Standish, ND, PhD, Lac, FABNO (SUB_INVESTIGATOR)
Sunil K Aggarwal, MD, PhD, FAAPMR (SUB_INVESTIGATOR)
Sonia S Malani, ND (SUB_INVESTIGATOR)

Find similar trials in Seattle, WA

By research site
AIMS Institute· Seattle, WA

Related Studies